Clinical Trials Browser

INDUSTRY × Platinum-Sensitive Ovarian Cancer in First Relapse × Clear all

NCT02289950 2021-09-02

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Phase 2 Completed

332 enrolled 14 charts

Platinum-Sensitive Ovarian Cancer in First Relapse